Form SCHEDULE 13G Acumen Pharmaceuticals, Filed by: MURRAY JAMES B JR

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

James B. Murray Jr.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,468,465.00
6	Shared Voting Power 142,895.00
7	Sole Dispositive Power 3,468,465.00
8	Shared Dispositive Power 142,895.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,611,360.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.00 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: This Schedule 13G is being filed late due to an inadvertent oversight.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Acumen Pharmaceuticals, Inc.

(b)

Address of issuer's principal executive offices:

1210-1220 Washington Street, Suite 210, Newton, Massachusetts 02465

Item 2.

(a)

Name of person filing:

James B. Murray Jr.

(b)

Address or principal business office or, if none, residence:

c/o Murray Enterprises, LLC 427 Park Street Charlottesville, VA 22902

(c)

Citizenship:

United States of America

(d)

Title of class of securities:

Common Stock, $0.0001 par value per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

As of April 6, 2026, Mr. Murray beneficially owned 3,611,360 shares of the Issuer's Common Stock, consisting of: (i) 3,468,465 shares held by James B. Murray, Jr., as Trustee of the James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991 and (ii) 142,895 shares held by Praxis Technologies LLC. James B. Murray, Jr. is a manager of Praxis Technologies, LLC and has the power to vote or dispose of shares held by the entity, along with another manager of Praxis Technologies, LLC. As of April 4, 2025, Mr. Murray beneficially owned 3,081,057 shares of the Issuer's Common Stock, consisting of: (i) 2,938,162 shares held by James B. Murray, Jr., as Trustee of the James B. Murray, Jr. Revocable Trust U/A/D 8/5/1991 and (ii) 142,895 shares held by Praxis Technologies LLC.

(b)

Percent of class:

Percent of Common Stock and total voting power of the Issuer's Common Stock is based on the denominator of 72,212,758 shares of the Issuer's Common Stock outstanding as of March 20, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 26, 2026. Based on the above, as of April 6, 2026, Mr. Murray beneficially owned 5.00% of the Issuer's outstanding Common Stock, representing 5.00% of the total voting power of the Issuer's outstanding Common Stock. As of April 4, 2025, Mr. Murray beneficially owned 5.01% of the Issuer's outstanding Common Stock, based on the denominator of 60,573,425 shares of the Issuer's Common Stock outstanding as of March 24, 2025, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

3,468,465

(ii) Shared power to vote or to direct the vote:

142,895

(iii) Sole power to dispose or to direct the disposition of:

3,468,465

(iv) Shared power to dispose or to direct the disposition of:

142,895

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

James B. Murray Jr.

Signature:	/s/ James B. Murray, Jr.
Name/Title:	James B. Murray, Jr.
Date:	04/07/2026

Form SCHEDULE 13G Acumen Pharmaceuticals, Filed by: MURRAY JAMES B JR

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed